Myelodysplastic Syndromes (MDS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Myelodysplastic Syndromes (MDS) Emerging Therapy and TPP Insights

Thelansis’s “Myelodysplastic Syndromes (MDS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Myelodysplastic Syndromes (MDS) Overview

Myelodysplastic syndrome (MDS) comprises a group of myeloid hematological disorders distinguished by reduced blood cell counts, abnormalities in the bone marrow, and a significant risk of evolving into acute myeloid leukemia (AML). Clinical manifestations primarily result from low blood cell counts, predominantly anemia, leading to fatigue, shortness of breath, and potentially angina. Less frequently, MDS may manifest as thrombocytopenia, resulting in spontaneous bleeding or neutropenia, making individuals susceptible to bacterial or, in rarer cases, fungal infections. The underlying cause remains unknown in 80% of cases. In the remaining 20%, it may be attributed to acquired factors such as prior chemotherapy or radiation therapy, occupational exposure to benzene derivatives or ionizing radiation, or inherited factors, including gene mutations mainly involving DDX41, GATA2, RUNX, and telomerase genes, or DNA instability (notably seen in Fanconi anemia patients who are prone to developing MDS).

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)